Prophylaxis News and Research

RSS

Special issue supports a national program to improve access to PrEP for preventing the spread of HIV

Researchers at the Johns Hopkins Bloomberg School of Public Health have contributed to a special issue of the Journal of Law, Medicine, and Ethics, including studies and commentary that support a national program to improve access to PrEP, a medication that prevents the spread of HIV.

29 Jul 2022

Yersinia pestis strains demonstrate susceptibility to 12 antimicrobial agents

Announcing a new article publication for Zoonoses journal. Streptomycin is the preferred choice for therapy of plague in China and other countries.

29 Jul 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

To stem the spread of monkeypox, health departments tap into networks of those most at risk

On July 23, the World Health Organization declared monkeypox a public health emergency of international concern.

27 Jul 2022

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

A new study reported the outcomes of a clinical trial evaluating the oral vaccine candidate against SARS-CoV-2 developed by Vaxart.

25 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Researchers describe viral shedding of monkeypox virus in patients to better understand the possible role of different bodily fluids in disease transmission

Researchers described the shedding of the monkeypox (MPX) virus (MPXV) in Barcelona city of Spain.

20 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 19 Jul 2022

Epidemiologic features of the June 2022 monkeypox outbreak in Spain

Researchers described epidemiologic features of monkeypox cases reported in Spain and the intervention measures taken to control the outbreak.

14 Jul 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Researchers investigate prevention and therapy against monkeypox infection

Researchers reviewed the preventive and therapeutic measures against monkeypox.

4 Jul 2022

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

Scientists have described the importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox infection.

4 Jul 2022

CDC data shows a sharp decrease in HIV testing during first year of COVID-19 pandemic

New CDC data published ahead of National HIV Testing Day (Monday, June 27) show a sharp decrease in the number of CDC-funded HIV tests administered in health care and non-health-care settings (43% and 50%, respectively) from 2019 to 2020, the first year of the COVID-19 pandemic.

28 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

23 Jun 2022

COVID-19 outcomes improved for SARDs patients through Omicron wave

In a recent study posted to the medRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19) incidence and severity among systemic autoimmune rheumatic diseases (SARDs) patients in Massachusetts, United States (US), between March 1, 2020, and January 31, 2022.

22 Jun 2022

Researchers assess monkeypox clinical management guidelines worldwide

A new study demonstrated the scarcity of appropriate clinical management guidelines for monkeypox infections across the globe.

20 Jun 2022

Illustrating a rapid response approach for monkeypox management

Researchers illustrated a rapid response strategy for managing monkeypox outbreaks.

20 Jun 2022

Fc-effector functions for selecting COVID-19 convalescent plasma

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment crystallizable (Fc)-effector activity result in effective prophylaxis.

15 Jun 2022

Two broadly neutralizing antibodies show promise to provide long-acting immunity against SARS-CoV-2

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

15 Jun 2022

Prophylaxis News and Research

Special issue supports a national program to improve access to PrEP for preventing the spread of HIV

Yersinia pestis strains demonstrate susceptibility to 12 antimicrobial agents

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

To stem the spread of monkeypox, health departments tap into networks of those most at risk

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Researchers describe viral shedding of monkeypox virus in patients to better understand the possible role of different bodily fluids in disease transmission

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Epidemiologic features of the June 2022 monkeypox outbreak in Spain

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Researchers investigate prevention and therapy against monkeypox infection

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

CDC data shows a sharp decrease in HIV testing during first year of COVID-19 pandemic

Bisphosphonates appear to improve COVID-19 exposure outcomes

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

COVID-19 outcomes improved for SARDs patients through Omicron wave

Researchers assess monkeypox clinical management guidelines worldwide

Illustrating a rapid response approach for monkeypox management

Fc-effector functions for selecting COVID-19 convalescent plasma

Two broadly neutralizing antibodies show promise to provide long-acting immunity against SARS-CoV-2

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News